Anaphylaxis

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

In 38 patients with house dust mite allergy, 18 months of SLIT was linked to early expansion and later reduction of allergen-specific type 2 memory B cells.

FDA updates, phase 3 CRISPR data in HAE, and emerging food allergy prevention strategies defined allergy and immunology news in April 2026.

Q&A with Le Thanh-Thao on trial data showing 25 mcg of JJA VIT matched 50 mcg efficacy, with safety and biomarker insights.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

The FDA has approved a labeling update for 1 mg epinephrine nasal spray permitting use in any patient weighing 33 lbs or more.

Research presented at AAAAI 2026 found that 88% of participants preferred intranasal epinephrine over injectables.

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

A randomized crossover study shows that most patients prefer intranasal epinephrine for anaphylaxis due to its ease of use, portability, and the absence of needles.

Expert panel identifies high agreement for multi-organ involvement, but uncertainty remains in moderate isolated skin or mucosal symptoms.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.